Unterehmen auf Watchlist setzen
Revance Therapeutics
ISIN: US7613301099
WKN: A1XD3D
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Revance Therapeutics · ISIN: US7613301099 · PR Newswire (ID: 20250115PH96703)
15 Januar 2025 06:00PM

Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit


BENSALEM, Pa., Jan. 15, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REVANCE THERAPEUTICS, INC. (RVNC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MARCH 4, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed alleges that, between February 29, 2024 and December 6, 2024, Defendants failed to disclose to investors that: (1) Revance was in material breach of the Distribution Agreement; (2) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (3) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:  

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:

Howard G. Smith, Esq.,

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Call us at: (215) 638-4847

Email us at: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/revance-therapeutics-inc-rvnc-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302351368.html

SOURCE Law Offices of Howard G. Smith

Visuelle Wertentwicklung / Kursverlauf · Revance Therapeutics
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942